Skip to main content
Equibles
LXEO logo

LXEO · Lexeo Therapeutics, Inc. · Metrics

Track LXEO — free

Use LXEO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LXEO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.87 +0.17 (+6.30%) At close · Oct 27 Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$221.52M
Shares
82.05M
Volume · Oct 27 2.68M Avg daily vol (3M) 1.28M

LXEO metrics

60 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.87
Market cap
$221.52M

Price action

20 metrics
Price change (1W)
-5.0%
Price change (30D)
-8.6%
Price change (3M)
-34.6%
Price change (6M)
-50.6%
Price change (YTD)
-71.1%
Price change (1Y)
-70.8%
Trailing year
Price change (5Y)
—
52-week high
$10.63
52-week low
$2.63
Change from 52-week high
-73.0%
Change from 52-week low
+9.1%
Annualized volatility
70.8%
Annualized volatility (3M)
66.8%
Beta
2.1
RSI (14D)
39.5
Price vs SMA 50
-25.9%
Price vs SMA 200
-45.7%
Avg volume (3M)
1.28M
Relative volume
2.1
Average dollar volume
$4.82M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
82.05M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.9
reciprocal yield 106.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-39.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-22

Profitability

9 metrics
Gross margin
—
Operating margin
-9,252.1%
Trailing 12 months
Net margin
-9,063.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$95.12M
Net income (TTM)
−$87.30M
Trailing 12 months
Diluted EPS (TTM)
$-0.82
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$3.38

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+96.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-37.1%
Return on assets
-34.3%
Debt / equity
—
Current ratio
13.9
EBITDA (TTM)
−$94.82M
Free cash flow (TTM)
—
Quick ratio
13.9
Interest coverage
-1,303.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$92.83M
Latest balance sheet
Cash & equivalents
$92.83M
Total assets
$254.90M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$88.37M
Capital expenditures (TTM)
$331,000
R&D (TTM)
$66.64M
SG&A (TTM)
—
Stock compensation (TTM)
$13.81M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
143
13F filer change QoQ
+3
Institutional ownership
107.6%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+8.8%
Holder tenure
6.1
Price vs estimated holder cost
-37.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.0%

Short interest

3 metrics
Short interest
21.4%
Latest settlement · 10.0 days to cover
Days to cover
10.0d
Short-squeeze score
62 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$43,228
Insider-sentiment score
39 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1907108 CUSIP 52886X107 13F (30d) 17 filings 17 filers Visit website Investor relations